Stocktoria
Absci Corp ABSI
Nasdaq · XNAS · stock · Services-Commercial Physical & Biological Research · website · IPO 2021-07-22
Absci Corp financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $2.8M | $4.5M | $5.7M | $5.7M | $4.8M |
| R&D expense | $81.4M | $63.9M | $48.1M | $58.9M | $44.6M |
| SG&A expense | $35.1M | $36.2M | $37.8M | $40.6M | $28.8M |
| Operating income | -$120.3M | -$108.9M | -$115.5M | -$106.8M | -$75.2M |
| Interest expense | — | — | $1.0M | $972,000 | $3.4M |
| Income tax | $69,000 | $70,000 | $100,000 | -$461,000 | -$8.9M |
| Net income | -$115.2M | -$103.1M | -$110.6M | -$104.9M | -$101.0M |
| EPS (diluted) | $-0.84 | $-0.94 | $-1.20 | $-1.15 | $-2.08 |
| Operating cash flow | -$92.9M | -$72.4M | -$64.6M | -$81.3M | -$60.6M |
| Free cash flow | -$94.0M | -$72.8M | -$65.5M | -$97.5M | -$98.6M |
| Cash & equivalents | $20.0M | $41.2M | $72.4M | $60.0M | $252.6M |
| Total assets | $216.3M | $213.6M | $217.3M | $321.0M | $426.2M |
| Total liabilities | $26.8M | $34.5M | $41.1M | $46.6M | $60.1M |
| Shareholders' equity | $189.4M | $179.1M | $176.2M | $274.4M | $366.1M |
Source: SEC EDGAR filings · CIK 0001672688 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.